Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 223

1.

Detection of early breast cancer beyond mammographic screening: a promising biomarker panel.

Hamann M, Grill S, Struck J, Bergmann A, Hartmann O, Pölcher M, Kiechle M.

Biomark Med. 2019 Sep;13(13):1107-1117. doi: 10.2217/bmm-2019-0085. Epub 2019 Aug 30.

PMID:
31468986
2.

Factors associated with the decline of psychological support in hospitalized patients with cancer.

Pichler T, Dinkel A, Marten-Mittag B, Hermelink K, Telzerow E, Ackermann U, Belka C, Combs SE, Gratzke C, Gschwend J, Harbeck N, Heinemann V, Herkommer K, Kiechle M, Mahner S, Pigorsch S, Rauch J, Stief C, Beckmann J, Heußner P, Herschbach P.

Psychooncology. 2019 Oct;28(10):2049-2059. doi: 10.1002/pon.5191. Epub 2019 Aug 16.

PMID:
31368613
3.

Increased Immune Activation by Pathologic α-Synuclein in Parkinson's Disease.

Grozdanov V, Bousset L, Hoffmeister M, Bliederhaeuser C, Meier C, Madiona K, Pieri L, Kiechle M, McLean PJ, Kassubek J, Behrends C, Ludolph AC, Weishaupt JH, Melki R, Danzer KM.

Ann Neurol. 2019 Oct;86(4):593-606. doi: 10.1002/ana.25557. Epub 2019 Aug 15.

PMID:
31343083
4.

Quantitative assessment and clinical relevance of kallikrein-related peptidase 5 mRNA expression in advanced high-grade serous ovarian cancer.

Gong W, Liu Y, Seidl C, Diamandis EP, Kiechle M, Drecoll E, Kotzsch M, Magdolen V, Dorn J.

BMC Cancer. 2019 Jul 15;19(1):696. doi: 10.1186/s12885-019-5901-0.

5.

Surgical Studies of Reconstructive Breast Surgery - An Overview of the Topics at the 2019 Annual Meeting of the Working Group for Reconstructive Surgery in Oncology-Gynecology.

Paepke S, Kiechle M, Ankel C, Weyrich J, Klein E, Schneider A, Johannigmann-Malek N, Dietrich AS, Ohlinger R, Thill M.

Geburtshilfe Frauenheilkd. 2019 Jun;79(6):584-590. doi: 10.1055/a-0873-8110. Epub 2019 Jun 14.

6.

Long-term Outcomes after Primary Radial Head Resection Arthroplasty vs. Acute Radial Head Resection vs. Secondary Prosthetic Removal in Comminuted Radial Head Fractures.

Kiechle M, Thannheimer A, Hungerer S, Friederichs J, Bühren V, Von Rüden C.

Arch Bone Jt Surg. 2019 Mar;7(2):112-117.

7.

Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification.

Parsons MT, Tudini E, Li H, Hahnen E, Wappenschmidt B, Feliubadaló L, Aalfs CM, Agata S, Aittomäki K, Alducci E, Alonso-Cerezo MC, Arnold N, Auber B, Austin R, Azzollini J, Balmaña J, Barbieri E, Bartram CR, Blanco A, Blümcke B, Bonache S, Bonanni B, Borg Å, Bortesi B, Brunet J, Bruzzone C, Bucksch K, Cagnoli G, Caldés T, Caliebe A, Caligo MA, Calvello M, Capone GL, Caputo SM, Carnevali I, Carrasco E, Caux-Moncoutier V, Cavalli P, Cini G, Clarke EM, Concolino P, Cops EJ, Cortesi L, Couch FJ, Darder E, de la Hoya M, Dean M, Debatin I, Del Valle J, Delnatte C, Derive N, Diez O, Ditsch N, Domchek SM, Dutrannoy V, Eccles DM, Ehrencrona H, Enders U, Evans DG, Farra C, Faust U, Felbor U, Feroce I, Fine M, Foulkes WD, Galvao HCR, Gambino G, Gehrig A, Gensini F, Gerdes AM, Germani A, Giesecke J, Gismondi V, Gómez C, Gómez Garcia EB, González S, Grau E, Grill S, Gross E, Guerrieri-Gonzaga A, Guillaud-Bataille M, Gutiérrez-Enríquez S, Haaf T, Hackmann K, Hansen TVO, Harris M, Hauke J, Heinrich T, Hellebrand H, Herold KN, Honisch E, Horvath J, Houdayer C, Hübbel V, Iglesias S, Izquierdo A, James PA, Janssen LAM, Jeschke U, Kaulfuß S, Keupp K, Kiechle M, Kölbl A, Krieger S, Kruse TA, Kvist A, Lalloo F, Larsen M, Lattimore VL, Lautrup C, Ledig S, Leinert E, Lewis AL, Lim J, Loeffler M, López-Fernández A, Lucci-Cordisco E, Maass N, Manoukian S, Marabelli M, Matricardi L, Meindl A, Michelli RD, Moghadasi S, Moles-Fernández A, Montagna M, Montalban G, Monteiro AN, Montes E, Mori L, Moserle L, Müller CR, Mundhenke C, Naldi N, Nathanson KL, Navarro M, Nevanlinna H, Nichols CB, Niederacher D, Nielsen HR, Ong KR, Pachter N, Palmero EI, Papi L, Pedersen IS, Peissel B, Perez-Segura P, Pfeifer K, Pineda M, Pohl-Rescigno E, Poplawski NK, Porfirio B, Quante AS, Ramser J, Reis RM, Revillion F, Rhiem K, Riboli B, Ritter J, Rivera D, Rofes P, Rump A, Salinas M, Sánchez de Abajo AM, Schmidt G, Schoenwiese U, Seggewiß J, Solanes A, Steinemann D, Stiller M, Stoppa-Lyonnet D, Sullivan KJ, Susman R, Sutter C, Tavtigian SV, Teo SH, Teulé A, Thomassen M, Tibiletti MG, Tischkowitz M, Tognazzo S, Toland AE, Tornero E, Törngren T, Torres-Esquius S, Toss A, Trainer AH, Tucker KM, van Asperen CJ, van Mackelenbergh MT, Varesco L, Vargas-Parra G, Varon R, Vega A, Velasco Á, Vesper AS, Viel A, Vreeswijk MPG, Wagner SA, Waha A, Walker LC, Walters RJ, Wang-Gohrke S, Weber BHF, Weichert W, Wieland K, Wiesmüller L, Witzel I, Wöckel A, Woodward ER, Zachariae S, Zampiga V, Zeder-Göß C, Investigators K, Lázaro C, De Nicolo A, Radice P, Engel C, Schmutzler RK, Goldgar DE, Spurdle AB.

Hum Mutat. 2019 Sep;40(9):1557-1578. doi: 10.1002/humu.23818.

8.

Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance.

Engel C, Fischer C, Zachariae S, Bucksch K, Rhiem K, Giesecke J, Herold N, Wappenschmidt B, Hübbel V, Maringa M, Reichstein-Gnielinski S, Hahnen E, Bartram CR, Dikow N, Schott S, Speiser D, Horn D, Fallenberg EM, Kiechle M, Quante AS, Vesper AS, Fehm T, Mundhenke C, Arnold N, Leinert E, Just W, Siebers-Renelt U, Weigel S, Gehrig A, Wöckel A, Schlegelberger B, Pertschy S, Kast K, Wimberger P, Briest S, Loeffler M, Bick U, Schmutzler RK; German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC).

Int J Cancer. 2019 May 13. doi: 10.1002/ijc.32396. [Epub ahead of print]

PMID:
31081934
9.

Potential Interactions of Biologically Based Complementary Medicine in Gynecological Oncology.

Drozdoff L, Klein E, Kalder M, Brambs C, Kiechle M, Paepke D.

Integr Cancer Ther. 2019 Jan-Dec;18:1534735419846392. doi: 10.1177/1534735419846392.

10.

Lymph node dissection in endometrial cancer and clinical outcome: A population-based study in 5546 patients.

Pölcher M, Rottmann M, Brugger S, Mahner S, Dannecker C, Kiechle M, Brambs C, Grab D, Anthuber C, von Koch F, Schnelzer A, Engel J.

Gynecol Oncol. 2019 Jul;154(1):65-71. doi: 10.1016/j.ygyno.2019.04.002. Epub 2019 Apr 23.

PMID:
31027900
11.

Evaluating the Demand for Integrative Medicine Practices in Breast and Gynecological Cancer Patients.

Schuerger N, Klein E, Hapfelmeier A, Kiechle M, Brambs C, Paepke D.

Breast Care (Basel). 2019 Mar;14(1):35-40. doi: 10.1159/000492235. Epub 2018 Oct 23.

PMID:
31019441
12.

Clinical Validation of PITX2 DNA Methylation to Predict Outcome in High-Risk Breast Cancer Patients Treated with Anthracycline-Based Chemotherapy.

Schmitt M, Wilhelm OG, Noske A, Schricker G, Napieralski R, Vetter M, Aubele M, Perkins J, Lauber J, Ulm K, Thomssen C, Martens JWM, Weichert W, Kiechle M.

Breast Care (Basel). 2018 Dec;13(6):425-433. doi: 10.1159/000493016. Epub 2018 Sep 28.

13.

High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer.

Bick U, Engel C, Krug B, Heindel W, Fallenberg EM, Rhiem K, Maintz D, Golatta M, Speiser D, Rjosk-Dendorfer D, Lämmer-Skarke I, Dietzel F, Schäfer KWF, Leinert E, Weigel S, Sauer S, Pertschy S, Hofmockel T, Hagert-Winkler A, Kast K, Quante A, Meindl A, Kiechle M, Loeffler M, Schmutzler RK; German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC).

Breast Cancer Res Treat. 2019 May;175(1):217-228. doi: 10.1007/s10549-019-05152-9. Epub 2019 Feb 6.

PMID:
30725383
14.

Clinical performance of an analytically validated assay in comparison to microarray technology to assess PITX2 DNA-methylation in breast cancer.

Schricker G, Napieralski R, Noske A, Piednoir E, Manner O, Schüren E, Lauber J, Perkins J, Magdolen V, Schmitt M, Ulm K, Weichert W, Kiechle M, Martens JWM, Wilhelm OG.

Sci Rep. 2018 Nov 15;8(1):16861. doi: 10.1038/s41598-018-34919-1.

15.

Acute radiodermatitis in modern adjuvant 3D conformal radiotherapy for breast cancer - the impact of dose distribution and patient related factors.

Borm KJ, Loos M, Oechsner M, Mayinger MC, Paepke D, Kiechle MB, Combs SE, Duma MN.

Radiat Oncol. 2018 Nov 7;13(1):218. doi: 10.1186/s13014-018-1160-5.

16.

Cancer clinical trials - Survey evaluating patient participation and acceptance in a university-based Comprehensive Cancer Center (CCC).

Kessel KA, Vogel MME, Kessel C, Bier H, Biedermann T, Friess H, Herschbach P, von Eisenhart-Rothe R, Meyer B, Kiechle M, Keller U, Peschel C, Bassermann F, Schmid R, Schwaiger M, Combs SE.

Clin Transl Radiat Oncol. 2018 Oct 4;13:44-49. doi: 10.1016/j.ctro.2018.10.001. eCollection 2018 Nov.

17.

Use of biologically-based complementary medicine in breast and gynecological cancer patients during systemic therapy.

Drozdoff L, Klein E, Kiechle M, Paepke D.

BMC Complement Altern Med. 2018 Sep 24;18(1):259. doi: 10.1186/s12906-018-2325-3.

18.

Model-based learning of local image features for unsupervised texture segmentation.

Kiechle M, Storath M, Weinmann A, Kleinsteuber M.

IEEE Trans Image Process. 2018 Jan 12. doi: 10.1109/TIP.2018.2792904. [Epub ahead of print]

PMID:
29994498
19.

Demand for integrative medicine among women in pregnancy and childbed: a German survey on patients' needs.

Schürger N, Klein E, Hapfelmeier A, Kiechle M, Paepke D.

BMC Complement Altern Med. 2018 Jun 15;18(1):187. doi: 10.1186/s12906-018-2249-y.

20.

Modifiable Lifestyle Factors: Opportunities for (Hereditary) Breast Cancer Prevention - a Narrative Review.

Lammert J, Grill S, Kiechle M.

Breast Care (Basel). 2018 Apr;13(2):109-114. doi: 10.1159/000488995. Epub 2018 Apr 20. Review.

21.

Mammography Screening 2.0 - How Can Risk-Adapted Screening be Implemented in Clinical Practice?: Results of a Focus Group Discussion with Experts in the RISIKOLOTSE.DE Project.

Fürst N, Kiechle M, Strahwald B, Quante AS.

Geburtshilfe Frauenheilkd. 2018 May;78(5):506-511. doi: 10.1055/a-0603-4314. Epub 2018 Jun 4.

22.

Costs and effects of intra-operative fluorescence molecular imaging - A model-based, early assessment.

Präger M, Kiechle M, Stollenwerk B, Hinzen C, Glatz J, Vogl M, Leidl R.

PLoS One. 2018 Jun 1;13(6):e0198137. doi: 10.1371/journal.pone.0198137. eCollection 2018.

23.

Introducing a novel highly prognostic grading scheme based on tumour budding and cell nest size for squamous cell carcinoma of the uterine cervix.

Jesinghaus M, Strehl J, Boxberg M, Brühl F, Wenzel A, Konukiewitz B, Schlitter AM, Steiger K, Warth A, Schnelzer A, Kiechle M, Beckmann MW, Noske A, Hartmann A, Mehlhorn G, Koch MC, Weichert W.

J Pathol Clin Res. 2018 Apr;4(2):93-102. doi: 10.1002/cjp2.95. Epub 2018 Mar 8.

24.

Advanced high-grade serous ovarian cancer: inverse association of KLK13 and KLK14 mRNA levels in tumor tissue and patients' prognosis.

Dettmar L, Ahmed N, Kotzsch M, Diersch S, Napieralski R, Darmoul D, Schmitt M, Weichert W, Kiechle M, Dorn J, Magdolen V.

J Cancer Res Clin Oncol. 2018 Jun;144(6):1109-1118. doi: 10.1007/s00432-018-2623-7. Epub 2018 Mar 15.

PMID:
29546479
25.

Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.

Engel C, Rhiem K, Hahnen E, Loibl S, Weber KE, Seiler S, Zachariae S, Hauke J, Wappenschmidt B, Waha A, Blümcke B, Kiechle M, Meindl A, Niederacher D, Bartram CR, Speiser D, Schlegelberger B, Arnold N, Wieacker P, Leinert E, Gehrig A, Briest S, Kast K, Riess O, Emons G, Weber BHF, Engel J, Schmutzler RK; German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC).

BMC Cancer. 2018 Mar 7;18(1):265. doi: 10.1186/s12885-018-4029-y.

26.

The Association between Serum 25-Hydroxyvitamin D and Cancer Risk: Results from the Prospective KORA F4 Study.

Cheney CP, Thorand B, Huth C, Berger K, Peters A, Seifert-Klauss V, Kiechle M, Strauch K, Quante AS.

Oncol Res Treat. 2018;41(3):117-121. doi: 10.1159/000485512. Epub 2018 Feb 27.

27.

Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Lammert J, Lubinski J, Gronwald J, Huzarski T, Armel S, Eisen A, Meschino WS, Lynch HT, Snyder C, Eng C, Olopade OI, Ginsburg O, Foulkes WD, Elser C, Cohen SA, Kiechle M, Narod SA, Kotsopoulos J.

Breast Cancer Res Treat. 2018 Jun;169(3):561-571. doi: 10.1007/s10549-018-4694-1. Epub 2018 Feb 5.

PMID:
29404807
28.

PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.

Absmaier M, Napieralski R, Schuster T, Aubele M, Walch A, Magdolen V, Dorn J, Gross E, Harbeck N, Noske A, Kiechle M, Schmitt M.

Int J Oncol. 2018 Mar;52(3):755-767. doi: 10.3892/ijo.2018.4241. Epub 2018 Jan 8.

29.

Age-dependent differences in DNA damage after in vitro CT exposure.

Gomolka M, Oestreicher U, Rößler U, Samaga D, Endesfelder D, Lang P, Neumaier K, Belka C, Niemeyer M, Kiechle M, Hasbargen U, Hübener C, Kirlum HJ, Kulka U, Rosenberger A, Walsh L, Baatout S, Kesminiene A, Lindholm C.

Int J Radiat Biol. 2018 Mar;94(3):272-281. doi: 10.1080/09553002.2018.1419302. Epub 2018 Jan 25.

PMID:
29319401
30.

The Predictive Value of PITX2 DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges.

Aubele M, Schmitt M, Napieralski R, Paepke S, Ettl J, Absmaier M, Magdolen V, Martens J, Foekens JA, Wilhelm OG, Kiechle M.

Dis Markers. 2017;2017:4934608. doi: 10.1155/2017/4934608. Epub 2017 Sep 12. Review.

31.

Knee arthrodesis versus above-the-knee amputation after septic failure of revision total knee arthroplasty: comparison of functional outcome and complication rates.

Hungerer S, Kiechle M, von Rüden C, Militz M, Beitzel K, Morgenstern M.

BMC Musculoskelet Disord. 2017 Nov 13;18(1):443. doi: 10.1186/s12891-017-1806-8.

32.

Feasibility of structured endurance training and Mediterranean diet in BRCA1 and BRCA2 mutation carriers - an interventional randomized controlled multicenter trial (LIBRE-1).

Kiechle M, Dukatz R, Yahiaoui-Doktor M, Berling A, Basrai M, Staiger V, Niederberger U, Marter N, Lammert J, Grill S, Pfeifer K, Rhiem K, Schmutzler RK, Laudes M, Siniatchkin M, Halle M, Bischoff SC, Engel C.

BMC Cancer. 2017 Nov 10;17(1):752. doi: 10.1186/s12885-017-3732-4.

33.

Clinical relevance of kallikrein-related peptidase 9, 10, 11, and 15 mRNA expression in advanced high-grade serous ovarian cancer.

Geng X, Liu Y, Diersch S, Kotzsch M, Grill S, Weichert W, Kiechle M, Magdolen V, Dorn J.

PLoS One. 2017 Nov 2;12(11):e0186847. doi: 10.1371/journal.pone.0186847. eCollection 2017.

34.

Smoking and physical inactivity increase cancer prevalence in BRCA-1 and BRCA-2 mutation carriers: results from a retrospective observational analysis.

Grill S, Yahiaoui-Doktor M, Dukatz R, Lammert J, Ullrich M, Engel C, Pfeifer K, Basrai M, Siniatchkin M, Schmidt T, Weisser B, Rhiem K, Ditsch N, Schmutzler R, Bischoff SC, Halle M, Kiechle M.

Arch Gynecol Obstet. 2017 Dec;296(6):1135-1144. doi: 10.1007/s00404-017-4546-y. Epub 2017 Oct 3.

PMID:
28975393
35.

Time trends (2006-2015) of quality indicators in EUSOMA-certified breast centres.

van Dam PA, Tomatis M, Marotti L, Heil J, Mansel RE, Rosselli Del Turco M, van Dam PJ, Casella D, Bassani LG, Danei M, Denk A, Egle D, Emons G, Friedrichs K, Harbeck N, Kiechle M, Kimmig R, Koehler U, Kuemmel S, Maass N, Mayr C, Prové A, Rageth C, Regolo L, Lorenz-Salehi F, Sarlos D, Singer C, Sohn C, Staelens G, Tinterri C, Audisio R, Ponti A; eusomaDB Working Group.

Eur J Cancer. 2017 Nov;85:15-22. doi: 10.1016/j.ejca.2017.07.040. Epub 2017 Sep 4.

PMID:
28881247
36.

Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1.

Ettl J, Klein E, Hapfelmeier A, Grosse Lackmann K, Paepke S, Petry C, Specht K, Wolff L, Höfler H, Kiechle M.

PLoS One. 2017 Sep 6;12(9):e0183917. doi: 10.1371/journal.pone.0183917. eCollection 2017.

37.

Tissue kallikrein-related peptidase 4 (KLK4), a novel biomarker in triple-negative breast cancer.

Yang F, Aubele M, Walch A, Gross E, Napieralski R, Zhao S, Ahmed N, Kiechle M, Reuning U, Dorn J, Sweep F, Magdolen V, Schmitt M.

Biol Chem. 2017 Sep 26;398(10):1151-1164. doi: 10.1515/hsz-2017-0122.

PMID:
28755528
38.

The Golgi-localized, gamma ear-containing, ARF-binding (GGA) protein family alters alpha synuclein (α-syn) oligomerization and secretion.

von Einem B, Eschbach J, Kiechle M, Wahler A, Thal DR, McLean PJ, Weishaupt JH, Ludolph AC, von Arnim CAF, Danzer KM.

Aging (Albany NY). 2017 Jul 15;9(7):1677-1697. doi: 10.18632/aging.101261.

39.

Mobile Health in Oncology: A Patient Survey About App-Assisted Cancer Care.

Kessel KA, Vogel MM, Kessel C, Bier H, Biedermann T, Friess H, Herschbach P, von Eisenhart-Rothe R, Meyer B, Kiechle M, Keller U, Peschel C, Schmid RM, Combs SE.

JMIR Mhealth Uhealth. 2017 Jun 14;5(6):e81. doi: 10.2196/mhealth.7689.

40.

Induction of cathepsin B by the CXCR3 chemokines CXCL9 and CXCL10 in human breast cancer cells.

Bronger H, Karge A, Dreyer T, Zech D, Kraeft S, Avril S, Kiechle M, Schmitt M.

Oncol Lett. 2017 Jun;13(6):4224-4230. doi: 10.3892/ol.2017.5994. Epub 2017 Apr 5.

41.

Gynecologic oncologists' attitudes and practices relating to integrative medicine: results of a nationwide AGO survey.

Klein E, Beckmann MW, Bader W, Brucker C, Dobos G, Fischer D, Hanf V, Hasenburg A, Jud SM, Kalder M, Kiechle M, Kümmel S, Müller A, Müller MT, Paepke D, Rotmann AR, Schütz F, Scharl A, Voiss P, Wallwiener M, Witt C, Hack CC.

Arch Gynecol Obstet. 2017 Aug;296(2):295-301. doi: 10.1007/s00404-017-4420-y. Epub 2017 Jun 8.

42.

Validation of the German version of the Mediterranean Diet Adherence Screener (MEDAS) questionnaire.

Hebestreit K, Yahiaoui-Doktor M, Engel C, Vetter W, Siniatchkin M, Erickson N, Halle M, Kiechle M, Bischoff SC.

BMC Cancer. 2017 May 18;17(1):341. doi: 10.1186/s12885-017-3337-y.

43.

CXCR3 mediates ascites-directed tumor cell migration and predicts poor outcome in ovarian cancer patients.

Windmüller C, Zech D, Avril S, Boxberg M, Dawidek T, Schmalfeldt B, Schmitt M, Kiechle M, Bronger H.

Oncogenesis. 2017 May 15;6(5):e331. doi: 10.1038/oncsis.2017.29.

44.

Cancer of the ovary, fallopian tube, and peritoneum: a population-based comparison of the prognostic factors and outcomes.

Rottmann M, Burges A, Mahner S, Anthuber C, Beck T, Grab D, Schnelzer A, Kiechle M, Mayr D, Pölcher M, Schubert-Fritschle G, Engel J.

J Cancer Res Clin Oncol. 2017 Sep;143(9):1833-1844. doi: 10.1007/s00432-017-2422-6. Epub 2017 Apr 26.

PMID:
28447160
45.

Improved systemic treatment for early breast cancer improves cure rates, modifies metastatic pattern and shortens post-metastatic survival: 35-year results from the Munich Cancer Registry.

Hölzel D, Eckel R, Bauerfeind I, Baier B, Beck T, Braun M, Ettl J, Hamann U, Kiechle M, Mahner S, Schindlbeck C, de Waal J, Harbeck N, Engel J.

J Cancer Res Clin Oncol. 2017 Sep;143(9):1701-1712. doi: 10.1007/s00432-017-2428-0. Epub 2017 Apr 20.

PMID:
28429102
46.

Mammographic Density and Vitamin D Levels - A Cross-sectional Study.

Straub L, Riedel J, Luppa PB, Wissing J, Artmann A, Kiechle M, Seifert-Klauss VR.

Geburtshilfe Frauenheilkd. 2017 Mar;77(3):257-267. doi: 10.1055/s-0043-102694.

47.

C-Peptide, Baseline and Postprandial Insulin Resistance after a Carbohydrate-Rich Test Meal - Evidence for an Increased Insulin Clearance in PCOS Patients?

Stassek J, Erdmann J, Ohnolz F, Berg FD, Kiechle M, Seifert-Klauss V.

Geburtshilfe Frauenheilkd. 2017 Jan;77(1):59-65. doi: 10.1055/s-0042-119199.

48.

MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer.

Raychaudhuri M, Bronger H, Buchner T, Kiechle M, Weichert W, Avril S.

Breast Cancer Res Treat. 2017 Apr;162(3):511-521. doi: 10.1007/s10549-017-4132-9. Epub 2017 Feb 8.

49.

Lifestyle intervention in BRCA1/2 mutation carriers: study protocol for a prospective, randomized, controlled clinical feasibility trial (LIBRE-1 study).

Kiechle M, Engel C, Berling A, Hebestreit K, Bischoff S, Dukatz R, Gerber WD, Siniatchkin M, Pfeifer K, Grill S, Yahiaoui-Doktor M, Kirsch E, Niederberger U, Marter N, Enders U, Löffler M, Meindl A, Rhiem K, Schmutzler R, Erickson N, Halle M.

Pilot Feasibility Stud. 2016 Dec 19;2:74. doi: 10.1186/s40814-016-0114-7. eCollection 2016.

50.

Plasmin(ogen) serves as a favorable biomarker for prediction of survival in advanced high-grade serous ovarian cancer.

Zhao S, Dorn J, Napieralski R, Walch A, Diersch S, Kotzsch M, Ahmed N, Hooper JD, Kiechle M, Schmitt M, Magdolen V.

Biol Chem. 2017 Jun 27;398(7):765-773. doi: 10.1515/hsz-2016-0282.

PMID:
27935848

Supplemental Content

Loading ...
Support Center